Tarsus Pharmaceuticals, Inc. (TARS) stock
TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/304% above fair value
$78.20−0.48 (-0.61%)
Close on Nov 17, 2026Market cap $3.43BP/E –Yield 0.00%
Tarsus Pharmaceuticals price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Tarsus Pharmaceuticals's price to book ratio was 9.6× on Nov 11, 2026, against 10.1× a year earlier. Over the last 5 years it ranged from 1.7× to 10.4×, with a median of 4.8×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 9.6× | −0.8 |
| 2025 | Dec 31, 2025 | 10.4× | +1.5 |
| 2024 | Dec 31, 2024 | 8.9× | +5.8 |
| 2023 | Dec 29, 2023 | 3.1× | +1.2 |
| 2022 | Dec 30, 2022 | 1.9× | −0.7 |
| 2021 | Dec 31, 2021 | 2.6× | – |
See a number that looks wrong?